180results about How to "Good process reproducibility" patented technology

The invention relates generally to processes for producing electrically conductive noble metal thin films on a substrate by atomic layer deposition. According to one embodiment of the invention a substrate with a surface is provided in a reaction chamber and a vaporised precursor of a noble metal is pulsed into the reaction chamber. By contacting the vaporised precursor with the surface of the substrate, no more than about a molecular layer of the metal precursor is formed on the substrate. In a next step, a pulse of molecular oxygen-containing gas is provided in the reaction chamber, where the oxygen reacts with the precursor on the substrate. Thus, high-quality metal thin films can be deposited by utilising reactions between the metal precursor and oxygen. In one embodiment, electrically conductive layers are deposited in structures that have high aspect ratio vias and trenches, local high elevation areas or other similar surface structures that make the surface rough.

The invention provides a Loxoprofen sodium sustained release preparation, wherein the preparation comprises Loxiprofen sodium as active component and pharmaceutically acceptable carrier, the components include (1) skeleton type, membrane control type, or penetration pump type tablet or capsule, (2) microcapsule, small pill, microballoon, emulsion, and slow release preparation, (3) space or time delay type slow release preparation.

The invention provides a resin finishing agent composition for purified cotton clothes and a preparing method thereof. The resin finishing agent composition is a multi-ingredient resin finishing agent prepared by using etherified modified glyoxal resin, vinol, a polyethylene softener, an organic siloxane softener, MgCl2.6H2O, water and the like as main parts. The resin finishing agent composition is used in three-dimensional cat whisker crumpling finishing of pure cotton clothes. Compared with the conventional resin finishing agent, the resin finishing agent composition of the invention simplifies production technology and reduces operation and technology difficulties; and after finishing, fabrics have strength retention of 65-75%, a wrinkle recover angle (WRA/degree) is greater than 254 degrees, and the cat whisker three-dimensional retention effect reaches four to five level.

The invention relates to a light absorption layer material of a thin film solar cell and a preparation method thereof. The light absorption layer material adopts Cu2SixSn1-xS3 semiconductor film or Cu2GexSn1-xS3 semiconductor film (X is equal to 0 to 1) in Cu2MS3 (M is Si, Ge or Sn) serial compounds. The preparation method comprises the steps that a Cu-Si-Sn alloy prefabricated layer or a Cu-Ge-Sn alloy prefabricated layer is deposited on a substrate through magneto-sputtering firstly, and then the vulcanization treatment is performed to the prefabricated layer. The material and the preparation method can solve the problems with the resource shortage and the environmental pollution in the development of the prior solar cell, and open up a new way for the development of the solar cell.

A process for preparing the superfine powder of sea cucumber includes washing fresh sea cucumber, removing impurities, cutting, freeze vacuum drying, breaking, and superfine pulverizing by fluidized-bed airflow. Its advantages are no pollution and easy absorption.

In order to automatically adjust a self-bias on a substrate to a constant value at all times and to form a high-quality insulating film with excellent process reproducibility, a vacuum thin film forming apparatus according to the present invention includes: a high-frequency sputtering device having a chamber, an evacuation means for evacuating the inside of the chamber, a gas introduction means for supplying gas into the chamber, a substrate holder provided within the chamber, and an electrode provided within the substrate holder; and at least one vacuum treatment chamber that can be selected from a group including a physical vapor deposition (PVD) chamber, a chemical vapor deposition (CVD) chamber, a physical etching chamber, a chemical etching chamber, a substrate heating chamber, a substrate cooling chamber, an oxidation treatment chamber, a reduction treatment chamber, and an ashing chamber, wherein the high-frequency sputtering device further includes a variable impedance mechanism electrically connected to the electrode for adjusting the potential of the substrate on the substrate holder.

The invention relates to a method for preparing rose superfine powder, which comprises: taking medicinal and edible fresh rose as a raw material, and performing impurity removal, cleaning and vacuum freeze-drying; and coarsely crushing the dried rose raw material, applying fluidized bed pneumatic milling technology for superfine processing, and preparing superfine powder products with water content between 6 and 8 and granularity between 1,000 and 3,000 meshes. The products produced by the method have the characteristics of uniform granularity, good dispersity, no processing pollution, capability of reserving bioactive compositions and thermosensitive compositions to the maximum degree, and not only can be quick to take health care effect and complete to absorb and digest but also can reduce the dosage and greatly improve the utilization rate of nutritive compositions of the rose.

The invention provides a precursor liposome containing di-demethoxycurcumin and a preparation method capable of industrial application. The weight ratio of the di-demethoxycurcumin to phospholipids together with phospholipid derivatives is 1:5-65, 3 to 20 portions of cholesterol together with derivatives thereof and 0.5 to 5 portions of surfactant are prepared into a freeze-dried powder injection according to the portion ratio of the phospholipids to freeze-drying protective agents being 1:0.25-4. The invention relates to a novel technique and a device for preparing a precursor liposome by an efficient jetting-mixing method, has the advantages of good process reproducibility, controllable technical parameters and the like, and can provide a unilocular liposome with fat-soluble medicaments which are stably wrapped in a phospholipid bilayer. The liposome has the average particle size of between 80 and 300 nm, is narrow in the distribution range of particle size, has entrapment rate of more than 85 percent, is low in leakage rate, and is significantly improved in the stability of preparation storage process. The in vivo circulation time of the novel preparation is obviously prolonged during intravenous injection administration, and the AUC of the novel preparation is 2.67 times that of the common injection.

The invention discloses a dexibuprofen slow release pellet and a preparation method thereof, and belongs to the field of medicinal preparations. The dexibuprofen slow release pellet comprises 50-80% of dexibuprofen, 0-5% of a slow release material, 0-2.5% of an adhesive, 8.75-47.5% of a filler, and 1.25-6.25% of a disintegrating agent, and all above percentages are based on the total weight of the pellet. The dexibuprofen slow release pellet has the advantages of good stability, stable quality, simple device and process, strong operationality, and suitableness for industrial large scale production. In vitro dissolution test shows that the accumulative release rate within 1h is 10-35%, the accumulative release rate within 2h is 25-55%, the accumulative release rate within 4h is 50-80%, and the accumulative release rate within 7h is 75% or above, so the dexibuprofen slow release pellet has a good release curve.

The invention discloses a levocetirizine dihydrochloride granule and preparation and detection methods thereof. The specification of the levocetirizine dihydrochloride particle is 2.5 mg, and milk sugar is used as filling agent. The levocetirizine dihydrochloride granule dispenses with the process of disintegration of tablets and capsules in a human body, the degree of dispersion in the human bodyis superior to the tablets and the capsules, and the absorption is faster than the tablets, the capsules and dispersible tablets; and the flowability, the dispersibility and the adhesiveness are better than the dispersible tablets, the granule is convenient to take, the mouthfeel is easier to adjust, and the curative effect of the medicine can be guaranteed to be better played.

The invention discloses a new formulation of a new non-steroidal anti-inflammatory drug zaltoprofen-a sustained-release preparation of the zaltoprofen and a preparation method thereof; each tablet/each granule of the zaltoprofen sustained-release preparation contains 80 to 240mg of the zaltoprofen and 10 to 120mg of excipients which play the sustained-release function; the sustained-release preparation is conductive to the long-term maintenance of the effective plasma-drug concentration and can improve the efficacy, reduce the side effects, reduce the times of being taken and facilitate the taking and the carry.

The invention relates to a tablet composition of anticoagulation medicament ticagrelor and a preparation method of the tablet composition. The tablet composition comprises ticagrelor, a filling agent, a disintegrating agent, a lubricating agent and/or an adhesive. The tablet composition is characterized in that a tablet is prepared by virtue of a direct compression method or a dry granulation compression method. The preparation method has the beneficial effects that the operation steps are simple, the controllability of process parameters is good, and the process repeatability is good; meanwhile, the crystal type transform and impurity increase which can be caused in damp and hot processes of ticagrelor are avoided; the prepared ticagrelor tablet has a similar in vitro dissolution behavior with a primarily researched preparation. Therefore, the ticagrelor tablet is stable and controllable in quality and good in treatment effect and safety.

The invention discloses a vitamin K1 micelle injection and a preparation method thereof, and belongs to the field of micelle injection and preparation thereof. The invention discloses a vitamin K1 micelle for the first time. The vitamin K1 micelle is prepared from vitamin K1, cholate, phospholipid, a pH regulator and water for injection. The preparation method of the vitamin K1 micelle injection comprises the steps that an organic solvent freezing and drying method is adopted, a mixed micelle composed of phospholipid and cholate is adopted as a carrier, and the vitamin K1 is entrapped in hydrophobic nuclei of the mixed micelle. Due to the fact that the vitamin K1 is not dissolved into water, the solubility of the vitamin K1 in water is remarkably improved through the cholate/phospholipid mixed micelle preparation technology, polysorbate-80 and propylene glycol are not added into the vitamin K1 micelle injection, only phospholipid and cholate named as physiological excipient are adopted as auxiliary materials, and compared with vitamin K1 injections on sale currently, the preparation can reduce adverse drug effect and improve the clinic application safety.

The invention relates to a method for preparing a compound controlled-release fertilizer from pulverized fuel ash serving as a raw material. The method comprises the following steps of: mixing a fertilizer, modified pulverized fuel ash, industrial aluminum hydroxide, sodium carbonate and polymeric aluminum ferric chloride; and pelletizing the mixture to obtain a compound controlled-release fertilizer. The method has the advantages of extensive raw material sources, low cost, simple production process, environmental friendliness and easiness for commercialization and supplies a new thought to comprehensive utilization of the pulverized fuel ash. By adopting the compound controlled-release fertilizer, nitrogen is fixed in the soil, so that the loss of the nitrogen can be reduced by 20 to 60percent, the utilization ratio of the compound fertilizer is increased, pollution of nitrogen to water bodies and the atmosphere is reduced, and good social benefit and economic benefit are achieved.

The invention discloses a drug composition containing rivastigmine, which comprises the active ingredient and the excipient of the rivastigmine and exists in the form of a troche.The drug composition is mainly used for curing senile dementia caused by alzheimer disease and paralysis agitans.

The invention discloses a graphene coated lead composite material and a preparation method thereof as well as a lead-acid battery. The graphene coated lead composite material comprises lead particles and a graphene layer covering the lead particles; the graphene layer is further doped with carbonate and stannous sulfate, and the mass ratio of carbonate to stannous sulfate to graphene in the graphene layer is (1-4):(0.01-0.06):1. The preparation method of the graphene coated lead composite material comprises the steps of preparing a precursor mixture of the graphene coated lead composite material and performing solvothermal reaction treatment on the mixture. The anode and the cathode of the lead-acid battery contain the graphene coated lead composite material. The graphene coated lead composite material is high in structural stability, electrical conductivity and capacitive performance; the preparation method of the graphene coated lead composite material is capable of guaranteeing even size distribution, and also is high in operability and environmentally friendly, and consequently, enlarged production can be realized. The lead-acid battery is excellent in specific capacity, charge-discharge performance and charge-discharge cycle performance, and long in service life.

The invention relates to an imatinib mesylate preparation, in particular to an imatinib mesylate liposome preparation. Imatinib mesylate liposome comprises blank liposome and imatinib mesylate liposome original medicines, the blank liposome comprises phospholipid, cholesterol, hydrophilic polymer lipid derivatives, citric acid-sodium citrate solution and alkaline substances, the mass ratio of imatinib mesylate to the phospholipid ranges from 1:8 to 1:30, the mass ratio of the cholesterol to the phospholipid ranges from 1:1 to 1:8, and the mole ratio of the hydrophilic polymer lipid derivatives to the phospholipid ranges from 1:30 to 1:10. A preparation process includes the steps of blank liposome preparation, liposome grading, medicine loading and the like. The imatinib mesylate liposome preparation is high in liposome embedding ratio, uniform in particle size, low in cost and good in process repeatability.

The invention relates to a composition liposome preparation used for medicines for treating tumors by injection drug administration and in particular relates to a preparation method of a compound composition liposome of ascorbyl palmitate and adriamycin. By combining the ascorbyl palmitate and the adriamycin, in-vivo and in-vitro experiments show that the anti-tumor drug function of the adriamycin can be remarkably enhanced, so that the adriamycin can express the drug effect under an extremely low dosage; the adriamycin is administrated in manners of vein drug administration, artery drug administration, muscle drug administration, subcutaneous drug administration, abdominal cavity drug administration and the like and is particularly used for interventional drug administration including intravenous infusion or intratumoral injection and the like, so that the effectiveness and safety of clinical application of the adriamycin are improved. The preparation method provided by the invention is simple in process and low in cost; prepared liposomes are uniform in particle diameter and high in entrapment efficiency and the drug releasing property is good; compared with a single liposome of the ascorbyl palmitate and the adriamycin, the effects of inhibiting the growth of the tumors in vitro and resisting proliferation of the tumors in vivo of the composition are remarkably enhanced.

The invention discloses clopidogrel hydrogen sulfate tablets. Each tablet contains 25-75mg of clopidogrel hydrogen sulfate based on clopidogrel and also comprises a filling agent, an adhesive and a lubricant, wherein the filling agent is beta-cyclodextrin or hydroxypropyl beta-hydroxypropyl; the adhesive is ethanol with volume concentration of 70%; and the lubricant is PEG-6000, PEG-4000 or PEG-2000. Special accessory is adopted in the product; and through the protection effect of the holes of the filling agent on the main drug and the water solubility of the adhesive, the prepared tablet has the characteristics of high dissolution rate, uniform appearance, good stability and the like, and can meet the requirements of industrial production.

The present invention provides an atorvastatin calcium submicroemulsion and a preparation method thereof. The atorvastatin calcium submicroemulsion comprises atorvastatin calcium (phospholipid complex form), an oil phase solvent, an emulsifier, a stabilizer, a potential modifier, glycerol and water, wherein the atorvastatin calcium phospholipid complex is used as a precursor drug so as to increase the solubility of atorvastatin calcium in the oil phase, and a molar ratio of atorvastatin calcium to the phospholipid is 1:1. According to the present invention, the drug-containing phospholipid complex is adopted as the precursor drug of atorvastatin calcium, such that the solubility and the stability of the drug in the oil phase are improved, the drug loading is increased, and the use of the high-concentration organic solvent can be avoided; and compared to the commercially available lipitor (atorvastatin calcium tablet), the atorvastatin calcium submicroemulsion of the present invention has the following characteristics that the absorption of the drug in the small intestine is improved, and the high blood drug level is provided and is maintained for a long time after the atorvastatin calcium submicroemulsion is orally taken so as to effectively improve the bioavailability of the drug.

A freeze-dried composite medicine is proportionally prepared from valacyclovir hydrochlorine and pharmacologicaly acceptable excipient through proportional mixing.

Disclosed are a substrate processing apparatus and a substrate processing method. The substrate processing apparatus includes an emissivity setting unit to which emissivity at a liquid chemical which is brought into contact with a substrate or emissivity at an interface at which the substrate and the liquid chemical are in contact with each other is input, a radiant energy input unit to which radiant energy radiating from the liquid chemical or the interface is input, and a calculation unit that calculates a calculation temperature of the liquid chemical or the interface based on the emissivity and the radiant energy.

The present invention relates to a magnesium chlorogenate medicine composition. It contains magnesium chlorogenate, magnesium isochlorogenate and chlorogenic acid, in which the content of magnesium chlorogenate is above 90%. Said medicine composition can be used for curing angiocardiopathy and cerebrovascular disease. Besides, said invention also provides its preparation method.

A component that is reflective for broadcast-frequency energy includes a nonmetallic substrate having a substrate surface, and a layered coating overlying and contacting the substrate. The layered coating has an electrically conductive layer overlying and contacting the substrate surface, and a layer of a white paint overlying and contacting the electrically conductive layer. The white paint is formed of a plurality of particles including a plurality of pigment particles. Each pigment particle has a composition of A[xAl(1−x)Ga]₂O₄(δD), A is selected from the group consisting of zinc, cadmium, and magnesium, D is a dopant selected from the group consisting of a cationic dopant having an ionic valence greater than +2 and an anionic dopant, the value of x is from 0 to 1, and the value of δ is from 0 to about 0.2. The paint further includes an inorganic or an organic binder mixed with the particles to form a mixture.